FARXIGA Drug Patent Profile

« Back to Dashboard

When do Farxiga patents expire, and when can generic versions of Farxiga launch?

Farxiga is a drug marketed by Astrazeneca Ab and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in FARXIGA is dapagliflozin. There is one drug master file entry for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the dapagliflozin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Farxiga

A generic version of FARXIGA was approved as dapagliflozin by AIZANT on April 6^th, 2026.

Summary for FARXIGA

US Patents:	17
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Raw Ingredient (Bulk) Api Vendors:	2
Clinical Trials:	50
Patent Applications:	1
Drug Prices:	Drug price information for FARXIGA
Drug Sales Revenues:	Drug sales revenues for FARXIGA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FARXIGA
What excipients (inactive ingredients) are in FARXIGA?	FARXIGA excipients list
DailyMed Link:	FARXIGA at DailyMed

See drug prices for FARXIGA

See drug sales revenues for FARXIGA

Recent Clinical Trials for FARXIGA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
UnitedHealthcare	PHASE2
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair	PHASE2
The University of Hong Kong	Phase 2

See all FARXIGA clinical trials

Pharmacology for FARXIGA

Drug Class	Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of Action	Sodium-Glucose Transporter 2 Inhibitors

Paragraph IV (Patent) Challenges for FARXIGA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FARXIGA	Tablets	dapagliflozin	5 mg and 10 mg	202293	20	2018-01-08

US Patents and Regulatory Information for FARXIGA

FARXIGA is protected by seventeen US patents and four FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes					Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes					Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes					Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014	AB	RX	Yes	No					Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes					Y
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014	AB	RX	Yes	Yes					Y

Expired US Patents for FARXIGA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-002	Jan 8, 2014
Astrazeneca Ab	FARXIGA	dapagliflozin	TABLET;ORAL	202293-001	Jan 8, 2014

EU/EMA Drug Approvals for FARXIGA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AstraZeneca AB	Forxiga	dapagliflozin	EMEA/H/C/002322Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease.	Authorised	no	no	no	2012-11-11
AstraZeneca AB	Edistride	dapagliflozin	EMEA/H/C/004161Type 2 diabetes mellitusEdistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureEdistride is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseEdistride is indicated in adults for the treatment of chronic kidney disease.	Authorised	no	no	no	2015-11-09
Viatris Limited	Dapagliflozin Viatris	dapagliflozin	EMEA/H/C/006006Type 2 diabetes mellitusDapagliflozin Viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance.- in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureDapagliflozin Viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.Chronic kidney diseaseDapagliflozin Viatris is indicated in adults for the treatment of chronic kidney disease.	Authorised	yes	no	no	2023-03-24

International Patents for FARXIGA

When does loss-of-exclusivity occur for FARXIGA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Canada

Chile

Denmark

European Patent Office

Japan

Mexico

Serbia

Slovenia

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering FARXIGA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	026024	COMPUESTOS INHIBIDORES SGLT2 DE GLUCOSIDOS DE C-ARILO Y METODO, LAS COMPOSICIONES FARAMCEUTICAS QUE LOS CONTIENEN Y LOS INTERMEDIARIOS DE SINTESIS DEDICHOS COMPUESTOS
Argentina	040032	C-ARIL-GLUCOSIDOS COMO INHIBIDORES DE SGLT2 Y METODO
Austria	295848
Austria	353334
Australia	2003237886	C-ARYL GLUCOSIDE SGLT2 INHIBITORS AND METHOD
Australia	781009
Australia	7848300	C-aryl glucoside sglt2 inhibitors

Supplementary Protection Certificates for FARXIGA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1506211	C300585	Netherlands		PRODUCT NAME: DAPAGLIFLOZINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211	PA2013008	Lithuania		PRODUCT NAME: DAPAGLIFLOZINUM; REGISTRATION NO/DATE: EU/1/12/795/001 - EU/1/12/795/010 20121112
1506211	122013000033	Germany		PRODUCT NAME: DAPAGLIFLOZIN UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211	C20130006 00074	Estonia		PRODUCT NAME: DAPAGLIFLOZIN;REG NO/DATE: K(2012)8378 12.11.2012
1506211	92182	Luxembourg		PRODUCT NAME: DAPAGLIFLOZINE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
1506211	2013/013	Ireland		PRODUCT NAME: DAPAGLIFLOZIN AND PHARACEUTICALLY ACCEPTABLE SALTS THREOF; REGISTRATION NO/DATE: EU/1/12/795/001-010 20121112
1506211	CA 2013 00019	Denmark

FARXIGA Market Dynamics, Financial Trajectory, Patent Exclusivity, and Generic Entry Risk

Last updated: October 9, 2026

FARXIGA, the brand name for dapagliflozin, is AstraZeneca’s largest cardiovascular-renal-metabolic growth product. Its commercial expansion from type 2 diabetes into heart failure and chronic kidney disease has materially extended the product’s addressable market beyond the diabetes segment. Revenue increased from roughly $1.5 billion in 2019 to approximately $5.8 billion in 2023, supported by new indications, global uptake, and guideline adoption. The principal medium-term risks are U.S. generic entry, pricing pressure, competition from Jardiance and other SGLT2 inhibitors, and the use of GLP-1 therapies in overlapping metabolic populations.

How has FARXIGA revenue changed over time?

FARXIGA revenue has followed an indication-driven growth curve rather than a traditional diabetes-only lifecycle.

Fiscal year	Estimated global FARXIGA revenue	Primary growth driver
2019	Approximately $1.5 billion	Type 2 diabetes and early cardiovascular adoption
2020	Approximately $2.0 billion	Heart-failure data and expanded prescribing
2021	Approximately $3.0 billion	Chronic kidney disease launch and cardiovascular use
2022	Approximately $4.4 billion	Global CKD and heart-failure penetration
2023	Approximately $5.8 billion	Broader cardio-renal-metabolic adoption

AstraZeneca reported continued strong demand for FARXIGA in its 2023 annual report, with sales growth driven by heart failure, chronic kidney disease and type 2 diabetes. The drug is now positioned as a cardio-renal-metabolic therapy rather than solely as a glucose-lowering product (AstraZeneca, 2024a).

The commercial importance of the product is substantial. FARXIGA is one of AstraZeneca’s key growth platforms alongside Tagrisso, Calquence, Imfinzi and Fasenra. Its revenue base helps offset declining sales from older oncology and respiratory products.

What indications support FARXIGA’s market expansion?

FARXIGA’s market expansion rests on four principal U.S. and international uses.

Type 2 diabetes

The FDA approved dapagliflozin in 2014 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. The diabetes market is competitive, with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, insulin and other SGLT2 inhibitors competing for treatment share.

FARXIGA’s diabetes value proposition includes oral administration, modest weight reduction, blood-pressure effects and cardiovascular-renal benefits that extend beyond hemoglobin A1c reduction.

Heart failure

The FDA approved FARXIGA to reduce the risk of cardiovascular death, hospitalization for heart failure and urgent heart-failure visits in adults with heart failure with reduced ejection fraction. Later label expansion supported use across broader heart-failure populations, including patients with preserved or mildly reduced ejection fraction.

This indication changed the prescribing base. Cardiologists, internists and hospital systems became important customers alongside endocrinologists and primary-care physicians.

Chronic kidney disease

In 2021, the FDA approved FARXIGA to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease at risk of progression.

The CKD indication increased the product’s potential population and created a treatment pathway in which nephrologists can prescribe dapagliflozin even when glycemic control is not the main clinical objective.

Pediatric type 2 diabetes

FARXIGA also received U.S. approval for use in certain pediatric patients aged 10 years and older with type 2 diabetes. The pediatric indication is commercially smaller than the adult cardio-renal indications but extends regulatory protection and supports guideline positioning.

How does FARXIGA compare with Jardiance and other SGLT2 inhibitors?

FARXIGA competes primarily with Jardiance, Invokana and Steglatro.

Product	Active ingredient	Principal company	Main competitive position
FARXIGA	Dapagliflozin	AstraZeneca	Broad heart-failure, CKD and diabetes positioning
Jardiance	Empagliflozin	Boehringer Ingelheim/Eli Lilly	Strong cardiovascular and heart-failure franchise
Invokana	Canagliflozin	Johnson & Johnson, with generic and legacy exposure	Early SGLT2 entrant with renal and diabetes data
Steglatro	Ertugliflozin	Merck/Pfizer legacy collaboration	Smaller commercial footprint

Jardiance is the closest branded competitor. Its cardiovascular outcomes data and strong diabetes-market presence have supported sustained competition. The two products are often evaluated within the same treatment class, although clinical guidelines and payer formularies may differentiate them by indication, trial evidence and contracting terms.

Invokana lost substantial momentum after early safety concerns and a more limited commercial position. Steglatro has remained a smaller participant.

The larger competitive threat is not limited to the SGLT2 class. GLP-1 receptor agonists such as Ozempic, Rybelsus, Wegovy and Mounjaro compete for patients with obesity, diabetes and cardiovascular risk. GLP-1 products generally provide greater weight loss, while FARXIGA has a stronger renal and heart-failure positioning. The therapies can be used together, which limits direct substitution in some treatment pathways.

What FDA regulatory milestones shaped FARXIGA’s commercial trajectory?

Date	Regulatory milestone
January 2014	FDA approval for adults with type 2 diabetes
2020	FDA approval for heart-failure risk reduction in patients with reduced ejection fraction
2021	FDA approval for chronic kidney disease risk reduction
2023	Broader heart-failure positioning, including patients across ejection-fraction categories
2024	Continued expansion of cardio-renal-metabolic use in clinical practice and guideline pathways

FARXIGA’s expansion demonstrates the value of outcome-trial evidence in extending a small-molecule product beyond its original metabolic indication. AstraZeneca has used the product’s clinical data to support adoption in cardiology and nephrology, where treatment decisions are often tied to hospitalization and disease-progression outcomes rather than glucose levels alone (U.S. Food and Drug Administration, 2024).

What patents protect FARXIGA?

FARXIGA has relied on a layered patent estate covering dapagliflozin, its crystalline form, pharmaceutical compositions and methods of use.

Patent or patent family	Subject matter	Expected U.S. relevance
U.S. Patent No. 6,515,117	C-aryl glucoside compounds, including dapagliflozin chemistry	Foundational composition protection; expired or substantially exhausted
U.S. Patent No. 8,501,698	Dapagliflozin propanediol monohydrate and related solid-state protection	Core formulation and crystalline-form protection
U.S. Patent No. 9,486,454	Therapeutic use and related dapagliflozin methods	Later-expiring method-of-use protection
Additional Orange Book-listed patents	Formulation, dosing and indication-specific protection	Potential barriers to a fully labeled generic launch

The foundational compound patent is no longer the principal commercial barrier. The key U.S. issue is the remaining term and enforceability of later patents covering the commercial salt or hydrate, formulations and specific uses.

Patent term adjustments, pediatric extensions, terminal disclaimers and litigation settlements can change the effective date of generic entry. The relevant date for a generic manufacturer is not simply the expiration date of the earliest composition patent. It is the earliest date on which an ANDA applicant can launch without infringing enforceable listed patents, subject to litigation outcomes and settlement terms.

What is the Orange Book status of FARXIGA?

FARXIGA is an FDA-approved small-molecule product listed in the Orange Book. Its Orange Book strategy has involved patents directed to the active ingredient, solid-state form, composition and methods of treatment.

The product does not receive biologic exclusivity. Generic companies can use the abbreviated new drug application pathway rather than the biosimilar pathway. Applicants may file Paragraph IV certifications challenging listed patents before their expiration.

The practical Orange Book risk is concentrated in the United States. In Europe, Canada, Japan and other markets, patent scope, supplementary protection certificates, national litigation and reimbursement rules differ by jurisdiction.

When does FARXIGA lose exclusivity?

FARXIGA’s regulatory exclusivity ended before its principal commercial patent protection. The five-year new chemical entity exclusivity associated with the 2014 approval expired in 2019, subject to applicable pediatric extension rules.

The commercial patent timetable is more important:

• Foundational compound protection has largely expired.
• The core dapagliflozin crystalline-form and formulation estate has been the principal U.S. barrier to generic entry.
• Method-of-use patents may continue to affect specific labeled indications after compound or formulation patents expire.
• Pediatric exclusivity can add six months to eligible patents or regulatory protections.
• Generic applicants may launch with a restricted label if they carve out patented indications.

Industry forecasts have generally placed meaningful U.S. generic competition around the middle of the decade, with exact timing dependent on ANDA litigation and settlement agreements. A generic launch could begin with a skinny-label product excluding certain heart-failure or CKD uses, then broaden as relevant patents expire or are invalidated.

Which companies are challenging FARXIGA patents?

Generic manufacturers commonly involved in dapagliflozin challenges and ANDA litigation include major Indian and U.S. generic companies, including Zydus, Teva, Sun Pharmaceutical, Lupin and related applicants. The precise list of active defendants changes as cases settle, consolidate or terminate.

Paragraph IV litigation typically addresses whether asserted patents are invalid, unenforceable or not infringed. For FARXIGA, litigation risk is concentrated in:

1. The crystalline-form or hydrate patent.
2. Formulation claims.
3. Method-of-use claims covering heart failure or CKD.
4. The timing and scope of authorized generic or settlement rights.

A court decision invalidating the core solid-state patent would accelerate generic entry across the main diabetes market. A decision upholding that patent would preserve branded pricing for a longer period, although method-of-use carve-outs could still permit partial generic competition.

What formulation and manufacturing barriers protect FARXIGA?

Dapagliflozin is a chemically defined small molecule, so manufacturing barriers are lower than for biologics, peptides or complex drug-device products. The most relevant technical protections involve:

• Control of the crystalline form and hydrate state.
• Purity and impurity profiles.
• Tablet formulation and dissolution performance.
• Stability under storage conditions.
• Bioequivalence to the reference product.
• Manufacturing processes that consistently produce the approved solid form.

These barriers can delay approval or increase litigation exposure, but they are generally less durable than biologic manufacturing know-how. Once a generic manufacturer develops a reproducible process and demonstrates bioequivalence, the technical moat is limited.

FARXIGA is available as oral tablets, which simplifies commercial substitution. There is no injectable delivery system or device-specific barrier comparable to insulin pens, inhalers or long-acting depot formulations.

What patent litigation and settlement risks affect FARXIGA?

FARXIGA’s litigation exposure is typical of a commercially important small molecule approaching patent expiry. AstraZeneca’s principal options include:

• Defending Orange Book patents in Paragraph IV cases.
• Negotiating launch dates with generic applicants.
• Protecting high-value cardio-renal indications through method-of-use claims.
• Using authorized-generic or supply arrangements to manage the post-expiration price curve.
• Shifting patients toward newer or less-exposed AstraZeneca products.

Settlement agreements can permit a generic launch before the outer expiration date. The economic value of a settlement depends on the agreed launch date, whether the generic can use the full label, whether multiple applicants receive entry rights and whether the settlement includes supply or license provisions.

What generic launch scenarios exist for FARXIGA?

Scenario	Market effect
Single generic launches after core patent expiry	Moderate initial price erosion; brand retains some share
Several generics launch simultaneously	Rapid price compression and formulary substitution
Skinny-label generic launches	Diabetes price pressure with slower erosion in CKD and heart failure
Core patent invalidated early	Accelerated erosion across the broad market
Authorized generic launched by AstraZeneca	Lower net prices but greater control over channel economics
Settlement-controlled entry	Predictable erosion beginning on an agreed date

The highest-risk scenario is simultaneous entry by several manufacturers with broad labeling. Generic SGLT2 tablets are relatively easy to distribute through retail and mail-order channels, and payers can substitute them quickly.

The lower-risk scenario is indication segmentation. A generic may initially exclude patented uses, allowing AstraZeneca to preserve some heart-failure and CKD revenue while losing diabetes volume.

How strong is the FARXIGA patent estate?

The patent estate is moderate rather than exceptionally strong.

Its strengths are:

• Large clinical evidence base supporting later method-of-use patents.
• Multiple indications with different treatment claims.
• Commercial importance that incentivizes enforcement.
• Regulatory and reimbursement entrenchment in cardiology and nephrology.

Its weaknesses are:

• Small-molecule chemistry with no biologic manufacturing barrier.
• Expiration of foundational composition protection.
• Oral tablet dosage form with straightforward bioequivalence.
• Potential for skinny-label generic competition.
• Multiple generic applicants with experience challenging solid-state and formulation patents.

The commercial moat is therefore increasingly based on clinical outcomes, guideline placement, payer contracts and physician familiarity rather than on long-dated composition-of-matter protection.

What is the revenue exposure to generic FARXIGA entry?

If FARXIGA revenue is approximately $5.8 billion globally, the United States represents a material portion of value even though AstraZeneca reports product sales by medicine rather than always disclosing a complete country-level breakdown.

A broad U.S. generic launch could produce:

• An initial decline in U.S. branded volume.
• Net price reductions through rebates and payer contracting.
• Greater pressure on diabetes sales than on specialist-led CKD and heart-failure use.
• International spillover as governments use U.S. generic pricing as a reference.
• Lower long-term growth but continued cash generation from protected or less substitutable indications.

The global decline would likely be gradual if patent expiry occurs at different times by country. European and other markets may experience earlier or later generic entry depending on supplementary protection certificates and national patent outcomes.

What licensing deals support FARXIGA’s commercial position?

Dapagliflozin originated from research associated with Bristol-Myers Squibb and AstraZeneca. The companies developed and commercialized the product through a collaboration, with AstraZeneca becoming the principal global commercial owner after changes to the diabetes collaboration structure.

The collaboration gave FARXIGA access to AstraZeneca’s global infrastructure while preserving the research and development contribution of the original partner. No licensing arrangement removes the basic risk of generic substitution, but commercialization rights, regional partnerships and supply agreements can influence net revenue recognition and market access.

What is the competitive outlook for FARXIGA?

FARXIGA’s growth is likely to slow as the product approaches U.S. generic exposure, but the underlying disease markets remain attractive.

Growth supports include:

• Rising prevalence of chronic kidney disease.
• Greater diagnosis of heart failure with preserved ejection fraction.
• Use in patients without diabetes.
• Guideline recommendations for SGLT2 inhibitors.
• Combination use with GLP-1 receptor agonists and other cardiometabolic drugs.
• Expansion in emerging markets.

Risks include:

• Jardiance competition.
• GLP-1-driven changes in diabetes treatment sequencing.
• Reimbursement restrictions.
• Genitourinary adverse effects and volume-depletion concerns.
• Generic entry and price erosion.
• Limited differentiation among SGLT2 products in payer tenders.

FARXIGA remains commercially durable because heart failure and CKD demand is less discretionary than diabetes prescribing. Its post-patent value will depend on how effectively AstraZeneca protects the branded product’s specialist uses and manages the transition from premium pricing to class-level volume.

Key Takeaways

• FARXIGA generated approximately $5.8 billion in global revenue in 2023, up sharply from its 2019 base.
• Its largest commercial expansion came from heart failure and chronic kidney disease, not from diabetes alone.
• Jardiance is the principal branded competitor; GLP-1 therapies are the main adjacent threat.
• U.S. regulatory exclusivity ended earlier, while later patents covering solid-state forms, formulations and uses provide the main commercial protection.
• FARXIGA is exposed to Paragraph IV challenges and likely mid-decade U.S. generic entry.
• A skinny-label generic launch could initially target diabetes while leaving some CKD and heart-failure value protected.
• The patent estate is moderate. Clinical evidence and guideline adoption now provide more protection than foundational chemistry patents.
• Revenue erosion will depend on the number of generic entrants, launch timing, label scope and AstraZeneca’s pricing strategy.

FAQs About FARXIGA Market Dynamics and Patents

Is FARXIGA a biologic or a small-molecule drug?

FARXIGA is a small-molecule drug containing dapagliflozin. Generic manufacturers use the ANDA pathway, not the biosimilar pathway.

Will generic dapagliflozin be cheaper than FARXIGA?

Yes. Generic entry should reduce pharmacy acquisition costs and payer net costs, although the size and speed of price erosion will depend on the number of entrants and formulary strategy.

Can a generic launch for diabetes but not heart failure?

Yes. A generic applicant may use a section 8 label carve-out to omit certain patented methods of use, subject to FDA approval and patent-law constraints.

Does FARXIGA compete directly with Ozempic?

They can compete in type 2 diabetes, but their clinical roles differ. FARXIGA has a stronger heart-failure and kidney-disease positioning, while Ozempic has greater weight-loss and glucose-lowering effects.

What will determine FARXIGA’s post-patent value?

The main variables are generic launch timing, the number of approved ANDAs, payer substitution, continued use in CKD and heart failure, international patent expiry dates and AstraZeneca’s ability to maintain branded clinical differentiation.

References

1. AstraZeneca. (2024a). Annual report and form 20-F 2023. AstraZeneca PLC.

2. AstraZeneca. (2024b). Full-year and fourth-quarter 2023 results. AstraZeneca PLC.

3. U.S. Food and Drug Administration. (2014). FDA approves Farxiga to treat type 2 diabetes. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2021). FDA approves therapy to reduce risk of kidney and heart complications in adults with chronic kidney disease. U.S. Department of Health and Human Services.

5. U.S. Food and Drug Administration. (2024). Farxiga prescribing information. U.S. Department of Health and Human Services.

6. U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,515,117: C-aryl glucoside compounds. U.S. Department of Commerce.

7. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,501,698: Dapagliflozin propanediol monohydrate. U.S. Department of Commerce.

8. U.S. Patent and Trademark Office. (2016). U.S. Patent No. 9,486,454: Methods of treating patients with dapagliflozin. U.S. Department of Commerce.

DrugChatter Q&A for FARXIGA

Has farxiga lost exclusivtiy patent in 2026?
Farxiga 10 mg?
Cost of farxiga in usa?
Farxiga generic approval date?
Farxiga patent protection usa?